RUBICON1,791.00

Rubicon Research Ltd.

· Pharma & Health
₹ CrorePeersSHILPAMEDSPARCSTARSUPRIYAPARKHOSPSTHYROCAREMETROPOLISMARKSANSMcap ₹29,568 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)432.58432.58
Receivable Days (DSO)105.86105.86
Payable Days (DPO)223.98217.00
Cash Conversion Cycle (days)314.46321.44
Working Capital Turnover2.072.29
Asset Turnover0.750.75
Cash Conversion (CFO/Net Income)0.830.83
CFO/EBITDA0.510.51
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.